Kyverna Therapeutics (KYTX) Stock: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$7.26
-0.09 (-1.22%)
▼
5d:
-13.05%
30d:
-9.81%
90d:
-7.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KYTX is down 13.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KYTX is down 13.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $7.26, which is considered oversold relative to its 30-day fair value range of $7.73 to $8.60.
Technical Outlook: Technically, KYTX is in a downtrend. The price is currently testing key support at $7.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KYTX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.40 (+318.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KYTX is in a downtrend. The price is currently testing key support at $7.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KYTX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.40 (+318.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.73 -
$8.60
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 318.7% below Wall St target ($30.40)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.73 -
$8.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.21
Resistance Level
$8.78
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.36
Wall Street Target
$30.40
(+318.7%)
Share & Embed Analysis
Last updated: September 13, 2026 11:50 AM ET
Data refreshes hourly during market hours. Next update: 12:50 PM
Data refreshes hourly during market hours. Next update: 12:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
